MetaVia Inc.
MTVA
Rang în acțiuni
#32887
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Preț acțiune
$1.28
Ultima sincronizare: 2026-10-20
Capitalizare de piață
$8.43M
Schimbare (1 zi)
4.07%
Schimbare (1 an)
-21.47%
Țară
US
Tranzacționează MetaVia Inc. (MTVA)
Categorie
Healthcare
Câștiguri pentru MetaVia Inc. (MTVA)
Câștiguri în Jun 2026 TTM: $-14.45M
Conform celor mai recente rapoarte financiare ale MetaVia Inc., câștigurile actuale ale companiei sunt $-14.45M. În anul 2023, compania a înregistrat un câștig de $-12.47M, o creștere față de câștigului din 2022, care a fost de $-13.97M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru MetaVia Inc. din 2014 până în 2026
Câștiguri la sfârșitul fiecărui an
| An | Câștiguri | Schimbă |
|---|---|---|
| 2026 (TTM) | $-14.45M | -47.64% |
| 2024 | $-27.59M | 121.27% |
| 2023 | $-12.47M | -10.72% |
| 2022 | $-13.97M | -8.62% |
| 2021 | $-15.28M | -48.50% |
| 2020 | $-29.68M | 39.25% |
| 2019 | $-21.31M | 37.24% |
| 2018 | $-15.53M | -53.53% |
| 2017 | $-33.42M | 129.09% |
| 2016 | $-14.59M | 61.55% |
| 2015 | $-9.03M | 2,721.56% |
| 2014 | $-320.00K | 0.00% |
Câștiguri pentru companii similare sau concurente
| Companie | Câștiguri | Diferență de câștiguri | Țara |
|---|---|---|---|
| $5.27B | -36,614.61% |
US
|
|
| $-3.09B | 21,269.24% |
US
|
|
| $-4.02B | 27,701.44% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -13,603.05% |
NL
|
